REGAFFAIRS AI
Guide · 2026-11-20 · 3 min

CHMP: what EMA's medicines committee does and how it works

The CHMP is EMA's Committee for Medicinal Products for Human Use. It recommends whether a medicine gets EU authorisation. The Commission decides.

CHMP stands for the Committee for Medicinal Products for Human Use, the European Medicines Agency's scientific committee for human medicines. In the centralised procedure it assesses a medicine's quality, safety, efficacy and benefit-risk balance and recommends whether it should be authorised, but the legally binding marketing authorisation comes from the European Commission (EMA, European Commission).

What the CHMP does

The committee carries out the initial scientific assessment of EU-wide marketing authorisation applications. It also assesses variations and extensions to existing authorisations, considers safety recommendations and handles referrals of nationally authorised medicines that need an EU-harmonised position (EMA).

A centralised authorisation is valid in every EU country and in Iceland, Liechtenstein and Norway. Not every medicine goes through this route, because national procedures also exist. An EU authorisation also says nothing about national pricing, reimbursement or whether the product is actually on sale in a given country (EMA, EMA).

Standard evaluation takes up to 210 active days, excluding clock stops while the applicant prepares answers (EMA). Accelerated assessment can reduce that timeframe to 150 days, also excluding clock stops, for medicines of major public-health interest. Acceptance does not predetermine the final recommendation (EMA). Conditional marketing authorisation instead concerns authorisation on less comprehensive clinical data than is normally required, when specific criteria are met. It is valid for one year, can be renewed annually and carries specific obligations. The two mechanisms can be combined (EMA).

Is a positive CHMP opinion an approval?

No. Until the Commission's decision exists, the accurate phrase is "recommended for approval" (EMA). "CHMP approval" and "EMA approval" are common shorthand, but in a regulatory document, write what actually happened: an opinion, then a Commission decision.

Where to find CHMP meeting outcomes

EMA's CHMP page links the committee's meeting highlights, agendas and minutes, and is the entry point to the archive (EMA). Each document answers a different question, and they are not published at the same time.

DocumentWhat it tells youWhere
Meeting highlightsMain outcomes of a plenary, including new opinions. Not the Commission decision.CHMP page
AgendaBusiness planned for a meeting. Published before the plenary. It is not an outcome.CHMP page
MinutesThe formal record, published after the plenary that adopts them.CHMP page
EPARThe European public assessment report: assessment material, a public overview and product information for one medicine.EMA glossary
Union RegisterThe Commission decision, its date, annexes and authorisation status.Union Register

For a conditional authorisation, EMA's conditional marketing authorisation page explains where its specific obligations are published. Don't treat the existence of an EPAR as proof of a positive result. In the Union Register, use the register for medicinal products for human use, not the separate orphan designation register, because an orphan designation is not a marketing authorisation (Union Register).

CHMP opinions and the UK or US

A CHMP opinion doesn't license a medicine in the UK. Since 1 January 2025 the MHRA licenses medicines UK-wide, and European Commission authorisations are no longer valid in Northern Ireland (MHRA, updated 12 March 2025). In the US, the FDA runs its own evaluation before a drug can be sold, so an EU opinion carries no US approval status (FDA).

RegAffairs AI has a cited answer on what the CHMP does and where its outcomes are published.

Related guides